Medicare AdvantageCoverageMedium impact
MA06.035a, Rapid Whole Exome Sequencing (rWES) and Rapid Whole Genome Sequencing (rWGS) for Diagnosis of Genetic Disorders
Independence Blue Cross·Neurology, Pediatrics, Oncology +1 more·Medical Policy
Effective date
Dec 19, 2025
We identified it
Jun 19, 2026
Summary
Medicare Advantage policy MA06.035a for Rapid Whole Exome Sequencing (rWES) and Rapid Whole Genome Sequencing (rWGS) for genetic disorder diagnosis has been reissued with an effective date of December 19, 2025. This policy update affects coverage and billing requirements for advanced genetic testing procedures.
Action Required
By December 19, 2025: Billing team must review the complete MA06.035a policy document for updated coverage criteria, prior authorization requirements, and billing guidelines for rapid whole exome and genome sequencing. Contact Medicare Advantage plans to verify specific requirements for genetic testing claims before the effective date.